# Protagonist Therapeutics

Type: Company (PTGX)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/protagonist-therapeutics
Canonical HTML page: https://getbiobrief.com/entity/protagonist-therapeutics

## Timeline

- **2026-03-18**: Quarterly Earnings — Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
- **2025-Q4**: JNJ-2113 Phase 3 Progress — Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
- **2024-01-31**: Takeda Partnership — Protagonist signs a global licensing agreement for rusfertide with $300M upfront.

## Recent coverage (3 stories)

### PTGX's 2 Shot-on-Goal Strategy: ICOTYDE Approved, Rusfertide Priority Review, $620M Cash
2026-06-14 01:25:38 · Sentiment: Positive · Impact: 7/10 · Sources: 2

Protagonist Therapeutics has transitioned from binary clinical risk to execution risk, with ICOTYDE's FDA approval and rusfertide's Priority Review. Backed by $620 million in cash, the company's validated peptide platform and royalty-based revenue model offer a compelling biotech investment thesis.
Full story: https://getbiobrief.com/story/ptgx-2-shots-on-goal-icotyde-approved-rusfertide-priority-review

### Protagonist Therapeutics Braces for Q1 Earnings Amid Pipeline Milestones
2026-03-17 07:33:39 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
Full story: https://getbiobrief.com/story/protagonist-therapeutics-verbund-earnings-preview-2026

### Protagonist Therapeutics Surges 120% as Major Fund Trims $170M Stake
2026-02-25 21:44:08 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Protagonist Therapeutics has seen its share price skyrocket by 120% following significant clinical and regulatory milestones, yet a major institutional investor has disclosed a $170 million exit. This divergence highlights a classic 'sell the news' moment or strategic rebalancing amidst a period of high valuation for the peptide-based drug developer.
Full story: https://getbiobrief.com/story/protagonist-therapeutics-stock-surge-institutional-exit

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.